ORIENT-32 trial: sintilimab + bevacizumab biosimilar as a promising combination therapy in advanced hepatocellular carcinoma | Zendy

AI Assistant Blog Pricing

Open Access

ORIENT-32 trial: sintilimab + bevacizumab biosimilar as a promising combination therapy in advanced hepatocellular carcinoma

Author(s) -

Brandon Swed,

Omar Gandarilla,

Gagandeep Brar

Publication year - 2021

Publication title -

digestive medicine research

Language(s) - English

Resource type - Journals

ISSN - 2617-1627

DOI - 10.21037/dmr-21-73

Subject(s) - bevacizumab , biosimilar , hepatocellular carcinoma , medicine , oncology , chemotherapy

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom

About

About Careers Publisher Partners Contact Us Get Organisational Trial or Quote

Learn

FAQs Blog Terms of Use Privacy Policy

Download the Zendy App

Download on the

Discover

Explore

Copyright Knowledge E © 2026. All Rights Reserved.